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ABSTRACT
Human umbilical cord blood (UCB) hematopoietic progenitor cells (HPC) puriﬁed for high aldehyde dehydrogenase activity (ALDHhi) stimulate islet regeneration after transplantation into
mice with streptozotocin-induced b cell deletion. However, ALDHhi cells represent a rare progenitor subset and widespread use of UCB ALDHhi cells to stimulate islet regeneration will require
progenitor cell expansion without loss of islet regenerative functions. Here we demonstrate
that prospectively puriﬁed UCB ALDHhi cells expand efﬁciently under serum-free, xeno-free conditions with minimal growth factor supplementation. Consistent with the concept that ALDHactivity is decreased as progenitor cells differentiate, kinetic analyses over 9 days revealed the
frequency of ALDHhi cells diminished as culture time progressed such that total ALDHhi cell
number was maximal (increased 3-fold) at day 6. Subsequently, day 6 expanded cells (bulk
cells) were sorted after culture to reselect differentiated progeny with low ALDH-activity
(ALDHlo subset) from less differentiated progeny with high ALDH-activity (ALDHhi subset). The
ALDHhi subset retained primitive cell surface marker coexpression (32.0% 6 7.0% CD341/CD382
cells, 37.0% 6 6.9% CD341/CD1331 cells), and demonstrated increased hematopoietic colony
forming cell function compared with the ALDHlo subset. Notably, bulk cells or ALDHlo cells did
not possess the functional capacity to lower hyperglycemia after transplantation into
streptozotocin-treated NOD/SCID mice. However, transplantation of the repuriﬁed ALDHhi subset signiﬁcantly reduced hyperglycemia, improved glucose tolerance, and increased isletassociated cell proliferation and capillary formation. Thus, expansion and delivery of reselected
UCB cells that retain high ALDH-activity after short-term culture represents an improved strategy for the development of cellular therapies to enhance islet regeneration in situ. STEM
CELLS 2016;34:873–887

SIGNIFICANCE STATEMENT
Although fresh umbilical cord blood ALDHhi cells represent a promising population for the
stimulation of islet regeneration, the low number of ALDHhi cells in UCB limits widespread
application in diabetic patients. Clinical use of UCB ALDHhi cells to treat diabetes will require
expansion without compromising previously reported islet regenerative functions. In order to
generate more ALDHhi cells for regenerative applications, we developed a clinically applicable
culture protocol that resulted in a significant increase in ALDHhi cells in 6 days. High ALDHexpression was diminished as culture time progressed. Therefore, we re-selected expanded
progeny using ALDH-activity after culture, and compared the islet regenerative function of
more differentiated (ALDHlo) versus less differentiated (ALDHhi) subsets. Compared to
expanded progeny with low ALDH activity, the ALDHhi cell subset more highly expressed primitive cell surface markers, and demonstrated a pro-angiogenic transcription signature and
enhanced hematopoietic colony formation in vitro. Importantly, after transplantation into STZtreated NOD/SCID mice, only the re-selected ALDHhi cell subset improved hyperglycemia and
glucose tolerance via the stimulation of islet cell proliferation and islet re-vascularization.
Re-selection of UCB cell with high ALDH-activity after expansion represents an improved cell
therapy platform to augment islet regeneration in situ.

STEM CELLS 2016;34:873–887 www.StemCells.com

C AlphaMed Press 2015
V

Expanded ALDHhi Cells Promote Islet Regeneration

874

INTRODUCTION
Due to growing rates of obesity in an aging population, diabetes can be considered a global health care crisis. It is estimated that diabetes currently affects >260 million individuals
worldwide, and this number is expected to >360 million by
2030 [1]. There are two distinct types of diabetes; type 1 diabetes represents < 10% of cases and is associated with the
autoimmune destruction of insulin-secreting b cells, while
type 2 diabetes represents > 90% of cases and is linked with
insulin resistance leading to b cell dysfunction, and ultimately,
b cell exhaustion [1, 2]. The symptoms associated with b cell
loss and insulin deﬁciency in both type 1 and type 2 diabetic
patients are typically treated using exogenous insulin administration and/or oral glucose lowering agents. Because these
treatments do not provide “on-demand” glycemic control, diabetic patients have more extreme peaks and troughs in blood
glucose levels [3]. As a result, > 80% of diabetes patients will
develop severe vascular complications including peripheral
limb ischemia, heart attack, and stroke [4]. However, recent
analyses of type 1 patients with disease duration of >50years (medalists) has uncovered sustained c-peptide and proliferating b cells within the diabetic pancreas as evidence of
ongoing islet regeneration in the face of ongoing autoimmunity [4]. Thus, the human endocrine pancreas has the capacity
to regenerate if we can “tip the balance” in favor of islet
regeneration versus destruction during diabetes.
Whole pancreas or islet transplantation via the Edmonton
protocol suggests hyperglycemia in type 1 diabetes patients
can be effectively controlled via the replacement of viable b
cells [5–7]. However, continued autoimmune destruction of
donor islets, the need for lifelong immunosuppression, and
critical shortage of donor pancreas tissue have prevented
widespread use of these procedures [6, 7]. In the context of
cellular therapies for diabetes, the contribution of transplanted cells is not limited to the direct replacement of b
cells [1–3]. Cell therapies to re-establish functional b cell mass
in patients in situ have been an area of intense preclinical
study for >10 years. In our initial publication on islet regeneration [8], we demonstrated that transplantation of murine
bone marrow (BM)-derived c-kit1 HPC reduced hyperglycemia
in mice with streptozotocin (STZ)-induced b cell deletion.
Importantly, donor cells did not acquire insulin expression but
engrafted the pancreas and stimulated proliferation in recipient islets via undetermined paracrine activities [8]. Subsequent preclinical studies have shown that induction of bone
marrow-chimerism [9], or co-delivery of hematopoietic with
multipotent-stromal cells [10, 11] can induce islet recovery
and immune protection in autoimmune NOD mice [12]. Thus,
“stem cell-stimulated islet regeneration” has become a central
concept for pancreas repair, and may represent a feasible
approach to recover glycemic control in diabetic patients
[13–15].
Due to documented progenitor cell dysfunction in patients
with diabetes and vascular comorbidities [16–20], use of autologous progenitors to stimulate islet regeneration is predicted
to show reduced efﬁcacy [16]. Fortunately, recent government
initiatives to HLA-phenotype and cryopreserve umbilical cord
blood (UCB) samples for clinical applications has established a
readily available source of allogeneic cells early in ontogeny
and untouched by disease-related pathologies. To purify
C AlphaMed Press 2015
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regenerative progenitors from human UCB we use a ﬂuorescent substrate of aldehyde dehydrogenase (ALDH), a cytosolic
detoxiﬁcation enzyme highly expressed in long-lived progenitor cells [21]. Fluorescence activated cell sorting (FACS)-puriﬁed ALDHhi cells represent a rare subset of human UCB
(<0.5%) that coexpress primitive hematopoietic progenitor
cell surface markers [22–24]. After transplantation into immunodeﬁcient mice, ALDHhi cells demonstrated robust hematopoietic repopulating function [23, 24], widespread tissue
distribution [25], and angiogenesis-stimulating capacity in
ischemic hindlimbs [22, 26]. In STZ-treated NOD/SCID mice,
intravenous (i.v.) transplantation of BM or UCB ALDHhi cells
signiﬁcantly improved hyperglycemia and glucose tolerance,
while ALDHlo cell injected controls remained severely hyperglycemic [27, 28]. Temporal analyses after direct intrapancreatic delivery showed ALDHhi cells were transiently recruited to
regenerating islets and stimulated islet cell proliferation as
insulin expression was recovered [29]. Although fresh ALDHhi
cells represent a promising population for the stimulation of
islet regeneration, the low number of ALDHhi cells in UCB limits widespread application in diabetic patients.
Clinical use of UCB ALDHhi cells to treat diabetes will
require expansion without compromising islet regenerative
functions. Recently, in vitro methods that promote the rapid
expansion of UCB HPC with efforts to minimize differentiation
have been reported [30–32]. To generate more ALDHhi cells
for regenerative applications, we developed a serum free culture protocol that resulted in a threefold increase in ALDHhi
cells in 6 days. Because ALDH represents the rate-limiting
enzyme in the production of retinoic acid (RA), and RAsignaling paradoxically induces differentiation in hematopoietic cells [33, 34], high ALDH-expression was diminished as
culture time progressed. Therefore, we reselected expanded
progeny using ALDH-activity after culture, and compared the
islet regenerative function of more differentiated (ALDHlo) versus less differentiated (ALDHhi) subsets. Compared with
expanded progeny with low ALDH activity, the ALDHhi subset
highly expressed primitive cell surface markers, and demonstrated a proangiogenic transcription signature with enhanced
hematopoietic colony formation in vitro. Importantly, after
transplantation into STZ-treated NOD/SCID mice, only the
reselected ALDHhi subset improved hyperglycemia and glucose
tolerance via the stimulation of islet cell proliferation and islet
revascularization. Reselection of UCB HPC with high ALDHactivity after expansion represents an improved cell therapy
platform to augment islet regeneration in situ.

MATERIALS

AND

METHODS

hi

ALDH Cell Isolation from Human UCB
Human UCB was obtained with informed consent following
Cesarian section by phlebotomy of the umbilical vein at Victoria Hospital Birthing Centre, London, ON, Canada. The Human
Studies Research Ethics Board (HSREB) at Western University
approved all procedures. Within 24 hours of collection, UCB
samples were depleted of mature myeloid and lymphoid cells
(RosetteSep Human Cord Blood Progenitor Cell Enrichment
Cocktail, StemCell Technologies, Vancouver, Canada, www.
stemcell.com), and lineage-depleted (Lin2) cells were isolated
by Hypaque Ficoll centrifugation. This de-bulking step is
STEM CELLS
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performed to reduce the time required for cell sorting. Lin2
cells were then incubated with Aldeﬂour reagent (StemCell
Technologies), and FACS Aria III (BD Biosciences, Mississauga,
Canada, www.bdbiosciences.com) was used to select cells
with low side scatter and high ALDH-activity (ALDHhi cells) as
described previously [22–29]. We achieve > 98% ALDHhi cell
purity using this optimized selection protocol [22].

Expansion of UCB ALDHhi Cells In Vitro
Puriﬁed UCB ALDHhi cells were plated into ﬁbronectin coated
ﬂasks and expanded in X-vivo 15 media (Lonza, Basel, Switzerland) supplemented with 10 ng/ml thrombopoietin (TPO),
Fms-like tyrosine kinase 3 ligand (FLT-3L), and stem cell factor
(SCF) (Invitrogen, Burlington, Canada, www.thermoﬁsher.com)
for up to 9 days, with a media change every 3 days to minimize culture-induced cell differentiation [31].

Cell Surface Marker Expression on Expanded Progeny
At day 3, 6, or 9 expanded progeny were harvested and viable
cell numbers were assessed by trypan blue hemocytometer
counts. Expanded cells were reassayed with Aldeﬂour to quantify the frequency of cell progeny with low versus high ALDHactivity, and costained with 7-amino-actinomycin D viability dye.
Cells were labeled with anti-human antibodies for CD33 (myeloid), CD14 (monocytes), and CD11b (macrophages) to assess
ALDHhi cell differentiation in culture, or with CD34, CD38, and
CD133 to assess maintenance of primitive HPC phenotypes. Cell
surface marker expression for total expanded cell progeny, and
ALDHlo versus ALDHhi subsets, were acquired using an LSRII ﬂow
cytometer (BD Biosciences) and analyzed using FlowJo software.

Hematopoietic Colony Formation Assays
After 6 days expansion, total cell progeny was harvested, incubated with Aldeﬂuor reagent, and reselected by FACS for low
(ALDHlo cells) versus high (ALDHhi cells) ALDH-activity based
on Diethylaminobenzaldehyde (DEAB)-treated (ALDH1A1 inhibitor) controls. Bulk cells and ALDHlo or ALDHhi cell subsets
were seeded in methylcellulose media (H4434, Stem Cell
Technologies) at 500–1000 cells per well in 12-well plates,
performed in triplicate. Hematopoietic colonies formed were
phenotyped by morphologic assessment and quantiﬁed after
12–14 days in culture by light microscopy.

Microarray Analyses of Expanded ALDHlo and ALDHhi
Cell Subsets
After 6 days expansion, ALDHlo cell and ALDHhi cell subsets
were repuriﬁed by FACS and total mRNA from each subset
was extracted using mRNeasy mini kits (Qiagen, Dusseldorf,
Germany, www.qiagen.com). Microarray analyses were performed in triplicate on three individual UCB samples using a
total of 18 Affymetrix 1.0 human gene array chips at the
London Regional Genomics Facility. mRNAs more than twofold
differentially expressed between sample-matched ALDHlo versus ALDHhi cell subsets were analyzed using gene ontology
terms for membrane bound or secreted localization and
assessed for known cellular functions using Partek Genomics
Suite (Partek, St. Louis, MO, www.partek.com).

Transplantation of Hyperglycemic NOD/SCID Mice
NOD/SCID mice aged 7- to 10-week-old (Jackson Laboratories,
Bar Harbor, ME, www.jax.org) received intraperitoneal (i.p.)

www.StemCells.com
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injection with streptozotocin (35 mg/kg/day) for 5 consecutive
days as previously described [27–29]. On day 10, hyperglycemic (15–25 mmol/l) mice were sublethally irradiated (300cGy)
and transplanted by i.v. injection of phosphate-buffered saline
(PBS), or 106 bulk cells, 2 3 105 ALDHlo cells, or 2 3 105
ALDHhi cells. Systemic blood glucose concentrations were
monitored weekly for 42 days. Twenty-four hours before
euthanasia, mice were i.p.-injected with 200 lg 5-ethynyl-20 deoxyuridine (EdU, Invitrogen) to mark proliferating cells in
situ, and glucose tolerance tests (2 hour duration) were performed after i.p.-injection of 2 g/kg glucose bolus. Mouse
bone marrow and duodenal portion of the pancreas were collected, mechanically separated into a single cell suspension
and analyzed for human cells expressing human pan-leukocyte
marker CD45 and human nucleated cell marker HLA-A, B, C by
ﬂow cytometry or immunohistochemistry as described previously [29].

Immunohistochemistry and Immunofluorescence
The splenic portion of the pancreas was frozen in optimal cutting temperature media and cryostat sectioned at 10 mm, such
that each slide contained three sections that were 150 mM
apart. Pancreas sections stained with insulin for the quantiﬁcation of islet number, size, and b cell mass as described previously [27–29]. Insulin was costained with CD31 to quantify
islet capillary density; or with EdU to quantify b-cell proliferation by immunoﬂurescent microscopy [27–29].

Statistical Analyses
All data were expressed as mean 6 SEM. Analysis of signiﬁcance was performed by a two-way analysis of variance
(ANOVA) for resting blood glucose concentrations and ALDHhi
cell growth analysis, and by one-way ANOVA, followed by
Tukey’s test for all other analyses.

RESULTS
UCB ALDHhi Cells Proliferate Rapidly but Lose High
ALDH-Activity During Expansion
We have previously shown that UCB ALDHhi cells represent a
heterogeneous cell population primarily comprised of primitive hematopoietic/early myeloid progenitors with islet regenerative [28, 29] and proangiogenic functions [22]. However, a
typical UCB sample yields approximately 4 3 105 ALDHhi cells,
limiting the application of transplanted UCB HPC for human
therapy. To generate more cells for regenerative therapies, we
adapted in serum free, xeno-free conditions to expand ALDHhi
cells using minimal hematopoietic growth factor supplementation (10 ng/ml SCF, FLT-3L, TPO) [31, 32]. Lineage depleted
(Lin2) human UCB cells were ﬁrst puriﬁed based on low-side
scatter and high Aldeﬂour ﬂuorescence (Fig. 1A–1C).
1.7% 6 0.3% of UCB Lin2 cells expressed high ALDH-activity
(N 5 10). Puriﬁed UCB ALDHhi cells expanded efﬁciently in
serum free cultures (2.3 6 0.4-fold at day 3, 20.7 6 2.0-fold at
day 6, and 53.5 6 9.5-fold at day 9). However, the frequency
of cell progeny retaining high ALDH-activity diminished signiﬁcantly as culture time progressed from 29.5% 6 3.9% at day
3, 14.9% 6 1.5% day at 6, and only 2.2% 6 0.3% at day 9 (Fig.
1D–1F). Interestingly, at day 6, the expanded cell progeny
demonstrated a signiﬁcant increase (*, p < 0.05) in total
C AlphaMed Press 2015
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Figure 1. Isolation and expansion kinetics of puriﬁed human umbilical cord blood (UCB) ALDHhi cells. Representative ﬂow cytometry
showing the initial puriﬁcation of human UCB ALDHhi cells. Lineage depleted (Lin-) UCB cells were ﬁrst selected (R1) based on (A) forward and side scatter properties of mononuclear cells. (B): DEAB-treated controls established selection criteria (R2) for (C) ALDHhi cells
based on ALDH-activity. UCB ALDHhi cells represented 1.7% 6 0.3% of UCB Lin2 cells. (D–F): Representative ﬂow cytometry showing the
frequency of expanded progeny with high ALDH-activity after culture for 3, 6, or 9 days. The frequency of cells retaining high ALDHactivity was diminished as culture time progressed. (G–I): Fold increase in total ALDHhi cells, ALDHhi/CD341 cells, and ALDHhi/CD1331
cells was calculated at days 3, 6, or 9 compared with the number of cells seeded. Cell progeny at day 6 demonstrated signiﬁcant expansion of total ALDHhi cells, ALDHhi/CD341 cells, and ALDHhi/CD1331 cells. Data represent mean 6 SEM from 10 UCB samples (*,
p < 0.05). Abbreviations: DEAB, Diethylaminobenzaldehyde (DEAB); UCB, umbilical cord blood.

ALDHhi cells (3.1 6 0.4-fold, Fig. 1G). Cell surface molecules such
as CD34 and CD133 are commonly used to isolate primitive
cells with hematopoietic repopulating function, and expression
of these markers is also known diminish with cell maturation
and differentiation in vitro [33–35]. Total CD341 cells (2.3 6 0.3C AlphaMed Press 2015
V

fold, Fig. 1H) and CD1331 cells (2.0 6 0.4-fold, Fig. 1I) cells mirrored the expansion kinetics for ALDHhi cells, with slightly fewer
total cells generated at day 6. Thus, the 6-day time point was
selected for further analyses of ALDH subset-speciﬁc progenitor
cell surface phenotype after expansion.
STEM CELLS
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Expanded Cells with High ALDH-Activity Coexpress
CD34 and CD133 Surface Markers

Expanded Cells with High ALDH-Activity Displayed a
Proangiogenic Transcription Profile

After 6 days expansion, harvested cells were gated by FACS
based on ALDH activity using DEAB-inhibited controls (Fig.
2A), and bulk cells (R1), and ALDHlo cell (R2) or ALDHhi cell
(R3) subsets were analyzed for coexpression of primitive versus mature hematopoietic cell surface markers (Fig. 2B, 2C).
We have previously shown that CD34 (89.6% 6 5.9% CD341)
and CD133 (61.5% 6 2.3% CD341) were both highly coexpressed on fresh UCB ALDHhi cells [22]. Expanded cells with
ALDHlo phenotype signiﬁcantly downregulated CD34
(15.4% 6 4.7%) and CD133 (2.3% 6 0.9%) coexpression during
culture (Supporting Information Table S1). In contrast,
expanded cells with ALDHhi phenotype retained primitive
hematopoietic cell surface marker coexpression (69.3% 6 6.4%
CD341, 40.3% 6 8.1% CD1331, ***, p < 0.001, Supporting
Information Table S1). Similarly, the ALDHhi cell subset demonstrated hematopoietic repopulating cell surface phenotypes
(34% 6 6.6% CD341/CD382 and 41.6% 6 7.4% CD341/
CD1331, **, p < 0.01, Fig. 2D–2J). Expanded ALDHhi cells uniformly expressed the early myeloid marker CD33
(99.8% 6 0.1%), but did not acquire mature monocyte or macrophage markers (0.4% 6 0.1% CD141, 0.8% 6 0.2% CD11b1,
Supporting Information Table S1). Therefore, the expanded
ALDHhi subset retained primitive hematopoietic progenitor
cell surface phenotype without signiﬁcant differentiation over
6 days in culture. These data indicated that more differentiated (ALDHlo cells) versus less differentiated (ALDHhi cells)
subsets could be reselected after culture and directly compared for hematopoietic and islet regenerative functions.

Affymetrix microarray analyses from 3 expanded UCB samples
were performed in triplicate on matched ALDHlo cell versus
ALDHhi cell subsets repuriﬁed by FACS after 6 days culture.
These analyses identiﬁed 102 unique transcripts with signiﬁcantly increased (more than twofold and FDR of <1%, **,
p < 0.01) expression within the ALDHhi subset (Supporting
Information Fig. S1). These mRNA transcripts were ﬁltered
using gene ontology terms for plasma membrane or extracellular (secreted) localization and further analyzed for biological
function (Tables 1, 2). As an internal control for the reselection of cells with high ALDH-activity, ALDH1A1 mRNA expression was increased 3.72-fold in the ALDHhi versus ALDHlo
subset. To further validate the mRNAs encoding proteins with
plasma membrane localization, CD34 and PROM1 mRNA
expression was signiﬁcantly increased by the ALDHhi subset
correlating with increased CD34 and CD133 protein coexpression previously observed by ﬂow cytometry (Table 1, Fig. 2I).
Other transcripts highly expressed by the ALDHhi subset
encoded for hematopoietic / endothelial cell surface markers
(TIE1, TIE2), markers associated with myeloid cell proliferation
(IL1RL1, CRLF2, CD33), and cell surface-matrix adhesion
(ITAG9, ICAM3, SELL). mRNA transcripts with documented
association to proangiogenic processes are marked in bold
(Table 1). For mRNAs translating to proteins with extracellular
localization, the majority of transcripts highly expressed by
the ALDHhi subset encoded secreted proteins involved in
matrix reorganization that reduce inﬂammation (CRHBP,
HPDGS, PDXN) or promote angiogenesis (FREM1, CHF,
CHRDL1, FBN1, Table 2, marked in bold). Increased expression
of selected transcripts (IL-1RL1, ITAG9, CRHBP, FREM1) highly
expressed by expanded ALDHhi subset was validated using
independent UCB samples by qRT-PCR (Supporting Information Fig. S1). Interestingly, the transcripts of angiopoietin-2,
an agonist of the Tie receptor pathway, and cytokines that
synergize VEGF-dependant signals, including semaphorin 4A
(SEMA4A) and milk-fat globule-EGF factor 8 protein (MFGE8
or Lactadherin), were also upregulated in the expanded
ALDHhi subset using slightly less stringent selection criteria
(>1.5-fold and FDR of <5%, *, p < 0.05). Collectively, these
data suggested that the ALDHhi subset possessed a transcription proﬁle consistent with enhanced matrix adhesion and
proangiogenic functions.

Expanded Cells with High ALDH-Activity Retained
Hematopoietic CFU Function In Vitro
Fresh UCB ALDHhi cells are enriched for multipotent hematopoietic colony forming cell (HCFC) function in vitro (approximately 1 HCFC in 4 ALDHhi cells) [22]. To determine whether
expanded cells retained HCFC function after 6 days culture,
bulk cells, and resorted ALDHlo or ALDHhi subsets were analyzed for clonogenic hematopoietic colony formation after 14
days in methylcellulose media. For unselected cells, 6 days
culture resulted in a more than threefold reduction in HCFC
frequency (approximately 1 CFU in 13 Bulk Cells). Considering
total cell number was increased approximately 21-fold over 6
days, total HCFC within the expanded cells was approximately
sevenfold increased. Interestingly, the threefold expansion in
total ALDHhi cells correlated with a 2.5-fold reduction in the
frequency of CFU generated from cultured ALDHhi cells
(approximately 1 CFU in 10 expanded ALDHhi cells), leaving
the total HCFC content comparing fresh and expanded ALDHhi
cells relatively unchanged. Compared with ALDHlo subset
(approximately 1 CFU in 17 expanded ALDHlo cells), the frequency of HCFC was signiﬁcantly (*, p < 0.05) enriched within
the ALDHhi subset (Fig. 2K). Speciﬁcally, the expanded ALDHhi
subset formed signiﬁcantly more erythroblast and granulocyte
colonies compared with ALDHlo subset (Fig. 2L). Thus, total
HCFC content was signiﬁcantly increased after 6 days culture,
and the ALDHhi subset demonstrated enhanced hematopoietic
colony forming function compared with the ALDHlo subset.

www.StemCells.com

Transplantation of Expanded Cells with High
ALDH-Activity Reduced Hyperglycemia
We have previously shown that transplantation of fresh UCB
ALDHhi cells improved islet function in NOD/SCID mice with
STZ-induced hyperglycemia [28, 29]. To increase the number
of cells available for therapeutic applications, we set out to
expand UCB ALDHhi cells in serum-free, xeno-free hematopoietic culture conditions without the loss of islet regenerative
function after transplantation. STZ-treated, NOD/SCID mice
were ﬁrst transplanted with PBS or 106 bulk cells on day 10,
and blood glucose levels were assessed until day 42 (Fig. 3A).
Similar to PBS-injected controls, mice transplanted with bulk
cells remained severely hyperglycemic (>25 mmol/l, Fig. 3B),
suggesting the loss of islet regenerative function as a result of
6 day ex vivo expansion. Subsequently, total expanded cells
C AlphaMed Press 2015
V

Figure 2. Expanded cells with high ALDH-activity coexpressed primitive cell surface markers and showed enhanced hematopoietic colony formation in vitro. Representative ﬂow cytometry showing the puriﬁcation of expanded cell subsets after 6 days culture. (A): DEAB
controls were used to establish gates for (B) bulk cells (R1), or (C) ALDHlo cell (R2) or ALDHhi cell (R3) subsets. (D–I): Representative
ﬂow cytometry for primitive cell surface markers expressed on expanded cell subsets. (J): ALDHhi cells showed an increased frequency
of primitive CD341CD382 cells and CD341CD1331 cells compared with Bulk or ALDHlo cells. (K, L): Bulk, ALDHlo, or ALDHhi cells were
cultured in methylcellulose media and colonies of erythrocyte (BFU-E), granulocyte (CFU-G), and macrophage (CFU-M) lineages were
enumerated after 14 days. Compared with ALDHlo cells, ALDHhi cells were enriched for total hematopoietic colony formation of the
erythroblast and granulocyte lineages. Data represent mean 6 SEM from 5 to 6 umbilical cord blood samples (*, p < 0.05; **, p < 0.01).
Abbreviations: BFU, Burst Forming Unite; CFU, Colony Forming Unit; DEAB, Diethylaminobenzaldehyde.
C AlphaMed Press 2015
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Table 1. Transcripts with > 2.0-fold increased expression in expanded ALDHhi cells versus ALDHlo cells encoded hematopoietic and endothelial progenitor cell surface markers
Gene
Symbol

Common Names

Description

IL-1RL1

lnterleukin-1 receptor-like 1

GPR141

ITGA9

G protein-coupled receptor
141
T-cell lymphoma invasion and
metastasis 1
Integrin, alpha 9

PROM1

Prominin 1 or CD133











ANXA1

Annexin Al



CD34



IL12R82

Hematopoietic progenitor cell
antigen (slalomucin)
Calcitonin gene-related
peptide type 1 receptor
Intercellular adhesion
molecule 3
Interleukin 12 receptor, b 2

CRLF2
CD33

TIAM1

CALCRL
ICAM 3

SELL
TIE1
TIE2
CD200R

FC vs
ALDHlo
HPC

p-value vs
ALDHlo HPC

myeloid cell proliferation
macrophage activation
arteriole stiffness
wound healing
cell migration
cell-matrix adhesion
cell adhesion, chemotaxis
wound healing
hematopoiesis
vascular remodelling
cell migration
microsome secretion
cell-matrix adhesion
vascular remodelling
regulates SMC function
vasodilation
cell-matrix adhesion
regulates angiogenesis
cytokine-signalling
interferon c production
regulates angiogenesis
myeloid cell proliferation

7.55

3.40x104

4.11

1.373105

3.48

l.l83104

2.87

5.03x104

2.81

2.54x105

2.71

1.60x103

2.61

8.393103

2.34

1.24x103

2.32

9.17x104

2.14

8.603103

2.13

2.353103

cell-matrix adhesion
myeloid cell proliferation
cell adhesion
regulates angiogenesis
regulates EC migration,
survival and proliferation
 regulates EC migration,
survival and proliferation
 regulates inﬂammation
 regulates angiogenesis

2.11

9.90X103

2.09

1.863103

2.08

1.42x103

2.06

2.07x104

2.01

6.18x104

Biological Processes /
Pathways

Cytokine receptor-like factor 2



receptor for IL-33
activates ERK1 and ERK2
rhodopsin family receptor
adenylate cyclase activation
stimulates GDP-GTP exchange
activates RHO-like GTPases
receptor for VCAM1, osteopontin
activates integrin signalling
hematopoietic and vascular
progenitor cell marker
phospholipid-binding protein that
promotes exocytosis
hematopoietic and vascular
progenitor cell marker
G protein-coupled receptor
adenylate cyclase activation
ligands for the adhesion protein
integrin alpha-Ubeta-2
receptor for interleukin 12
coupling to the JAK/STAT pathway
receptor for thymic stromal
lymphopoietin
























Sialic acid-binding Ig-like
lectin 3 (Slglec-3)
Selectin L

 mediates sialic-acid dependent
binding to myelomonocytic cells
 promotes initial tethering /
rolling of leukocytes in endothelia
 tyrosine-protein kinase receptor
for ANGPT1. ANGPT2 and ANGPT4
 Tyrosine-protein kinase receptor
for ANGPT1. ANGPT2 and ANGPT4
 inhibits myeloid cell production
of TNFa, IFNc and iNOS







Tyrosine-kinase with Ig and
EGF homology
Tyrosine-prolein kinase
receptor Tla-2
Cell surface glycoprotein
CD200 receptor 1






were reselected for low versus high ALDH-activity (Fig. 2C)
after culture and i.v.-transplanted at 2 3 105 cells. This cell
dose was selected based on the availability of the ALDHhi subset (approximately 15–20% of total cells) and targeted to
deliver an equivalent total number of ALDHhi cells contained
within the unsorted population. Although mice transplanted
with the ALDHlo cell subset also remained severely hyperglycemic (>25 mmol/l, Fig. 3B), mice transplanted with reselected ALDHhi cells demonstrated signiﬁcantly (*, p < 0.05)
reduced systemic glucose from days 17–42 (Fig. 3B, 3C). Compared with mice transplanted with ALDHlo cells, mice transplanted with expanded ALDHhi cells also showed signiﬁcantly
(*, p < 0.05) improved glucose tolerance (Fig. 3D, 3E). Thus,
expanded UCB cells reselected for high ALDH-activity retained
glucose lowering function after transplantation into hyperglycemic mice.

Expanded Cells with High ALDH-Activity Consistently
Engrafted the Mouse Bone Marrow
To correlate improvement of glycemic control with human cell
engraftment, the bone marrow and the duodenal portion of
the pancreas were collected for all mice at day 42, and analyzed for the presence of human CD451 and HLA-ABC1 cells
by ﬂow cytometry. After i.v.-transplantation, only the culture
expanded ALDHhi cell subset consistently (7 of 9 mice) populated the murine BM (1.2% 6 0.7%, Supporting Information
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Fig. S2A–S2C, S2G). In contrast, transplantation of expanded
ALDHlo cells did not result in human hematopoietic engraftment, suggesting the ALDHlo subset had lost NOD/SCID repopulating capacity. Although expanded ALDHhi cells showed
reduced hematopoietic repopulating capacity compared with
our previous studies transplanting freshly isolated UCB ALDHhi
cells, blood glucose lowering capacity (Fig. 3B, 3C) was similar
to fresh ALDHhi cells previously reported [29]. Similar to transplanted fresh UCB ALDHhi cells, long-term human cell engraftment was not detected in mouse pancreata at day 42
(Supporting Information Fig. S2D–S2F). Importantly, lowfrequency human cell recruitment to the pancreas was conﬁrmed for expanded ALDHhi cells at 7 days posttransplantation (n 5 3 mice) by immunohistochemistry for
HLA-A, B, C (Fig. S2H). Collectively, expanded cells with high
ALDH-activity showed consistent but low frequency NOD/SCID
repopulating capacity but retained blood glucose-lowering
function despite low-level and transient pancreatic
engraftment.

Transplantation of Expanded Cells with High ALDHActivity Increased Islet Size
To investigate the mechanisms by which expanded ALDHhi
cells improved glycemic control, pancreas sections of transplanted mice were analyzed for insulin expression (Fig. 4A–
4D), and islet size (Fig. 4E), islet number (Fig. 4F), and total b
C AlphaMed Press 2015
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Table 2. Transcripts with > 2.0-fold increased expression in ALDHhi versus ALDHlo cells encoded extracellular matrix proteins that reduce
inﬂammation or promote angiogenesis
Biological Processes /
Pathways

Gene Symbol

Common Names

Description

CRHBP

PDXN

Corticotropin-releasing
hormone-binding protein
FRAS-1-related extracellular
matrix protein 1
Hematopoietic prostaglandin
D synthase
Peroxidasin homologue

TPSB2

Tryptase b-1

TNFSF10
CFH

Tumour necrosis factor
superfamily member 10
Complement factor H

CHRDL1

Chordin-like protein 1

FBN1

Fibrillin-1

 inactivates corticotropin inreleasing hormone (CRH) in ECM
 ECM protein that regulates cell
adhesion and differentiation
 matrix enzyme which catalyzes
the synthesis of Prostaglandin D2
 peroxidase in the vascular ECM
 H202 metabolism
 protease secreted upon activation - degranulation response
 binds TNFR / TRAIL receptors and
induces apoptosis
 heparin binding co-factor in complement activation pathway
 binds and inactivates BMP4 in
the ECM, potentiates VEGF
signals
 structural component of ECM
 sequesters TGFB and BMPs

FREM1
HPDGS

cell mass (Fig. 4G) were quantiﬁed. Compared with PBS
injected controls, mice transplanted with bulk or reselected
ALDHlo cells showed equivalent islet size, number and b cell
mass (Fig. 4E–4G). In contrast, mice transplanted with reselected ALDHhi cells showed a signiﬁcant (*, p < 0.05) increase
in islet circumference (Fig. 4E) and total b cell mass (Fig. 4G),
without increased total islet number. As previously reported
[28, 29], islets were comprised of murine insulin1 cells suggesting that transplantation of the ALDHhi subset improved
islet function through stimulation of endogenous islet recovery in situ.

Transplantation of Expanded Cells with High ALDHActivity Increased Islet Proliferation
Next we assessed islet-associated cell proliferation using EdUinjection 24 hours before euthanasia, and EdU incorporation
within islets was analyzed at day 42 (Fig. 5A–5D). Notably,
islets from all transplanted cohorts showed Edu1/Insulin2
cells (arrows), but transplantation of only the ALDHhi subset
resulted in the detection of Edu1/Insulin1 b cells. Compared
with mice transplanted with PBS, mice transplanted with reselected ALDHhi cells demonstrated a signiﬁcantly (*, p < 0.05)
higher frequency of islets with EdU1 proliferating cells (Fig.
5E), and an increased number of EdU1 islet cells/islet (Fig.
5F). Taken together, i.v.-transplantation of expanded UCB
ALDHhi cells stimulated islet-associated b cell proliferation in
situ.

Transplantation of Culture Expanded ALDHhi Cells
Increased Islet Capillary Density
We have previously shown that freshly isolated UCB ALDHhi
cells promote regenerating islet vascularization [28, 29]. Thus,
mouse pancreas sections were costained with insulin and
CD31, a marker for vessel-derived endothelial cells (Fig. 6A–
6D). When compared with mice from all other treatment
groups, intra-islet microvessel density was signiﬁcantly (*,
p < 0.05) increased in mice transplanted with the expanded
C AlphaMed Press 2015
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cellular stress response
reduces inﬂammation
cell-matrix adhesion
morphogenesis
SMC relaxation
reduces inﬂammation
ECM organization
reduces inﬂammation
immune response
activation of MMPs
immune response
cell-cell signalling
ECM organization
complement activation
ECM organization
promotes angiogenesis

 ECM organization
 promotes angiogenesis

FC vs
ALDHlo
HPC

p-value vs
ALDHlo HPC

6.70

1.81x1024

4.74

1.70x1023

3.75

1.05x1024

2.72

7.28x1024

2.44

7.42x1023

2.43

8.47x1023

2.26

2.34x1023

2.26

1.40x1023

2.01

2.54x1025

and reselected ALDHhi cell subset (Fig. 6E). Extra-islet capillary
density remained unchanged between all cohorts (Fig. 6F),
suggesting that transplantation of expanded cells with high
ALDH-activity stimulated islet-speciﬁc revascularization in situ.

DISCUSSION
The development of strategies to reestablish functional b cell
mass in patients with diabetes has been an area of intense
preclinical study over the past 10 years [1–3]. In our previous
studies, we established that freshly-isolated human UCB
ALDHhi cells could stimulate endogenous islet proliferation
and revascularization after transplantation into STZ-treated
mice [28, 29]. However, the low number of ALDHhi cells found
in UCB limits the widespread application of transplanted UCBderived cells in human diabetic patients. Kinetic analyses
revealed that UCB ALDHhi cells were highly proliferative in
serum-free culture. However, as culture time progressed the
frequency of cells retaining high ALDH-activity was decreased.
Thus, cell sorting based on the preservation of high ALDHactivity after culture was used to separate primitive progenitor cells (ALDHhi cells) from culture-differentiated, more committed cells (ALDHlo cells). Using sample-matched
comparisons with ALDHlo cell progeny, the 6-day expanded
ALDHhi cell subset retained primitive hematopoietic progenitor cell surface phenotype and colony forming function in
vitro, and demonstrated a proangiogenic transcriptional signature, Consistent with the conservation of primitive hematopoietic/endothelial phenotype and function, transplantation of
only the expanded reselected ALDHhi cells improved islet
function and b cell mass through augmentation of isletassociated cell proliferation and revascularization. Collectively,
we identify culture-expanded UCB cells with high ALDHactivity as a readily available population for the development
of clinical therapies to augment islet regeneration in situ.
Previous studies have shown that culturing UCB-derived
progenitor cells with hematopoietic cytokines results in a
STEM CELLS

Seneviratne, Bell, Sherman et al.

881

Figure 3. Transplantation of expanded cells with high ALDH-activity reduced hyperglycemia and improved glucose tolerance in STZtreated NOD/SCID mice. (A): STZ-treated NOD/SCID mice (35mg/kg/day, days 1-5) were sublethally irradiated and iv-injected with
phosphate-buffered saline (PBS) (blue, n 5 8), 106 bulk cells (orange, n 5 9), 2 3 105 ALDHlo cells (red, n 5 9), or 2 3 105 ALDHhi cells
(green, n 5 9) at day 10 and blood glucose was monitored for up to 42 days. (B, C): Compared with PBS-injected controls, or mice transplanted with Bulk or ALDHlo cells showed, mice transplanted with ALDHhi cells showed reduced resting blood glucose from days 17–42
and reduced area under the curve. (D, E): Compared with PBS-injected controls or mice transplanted with ALDHlo cells, mice transplanted with ALDHhi cells showed improved glucose tolerance and reduced area under the curve. Data represent mean 6 SEM from 5
to 7 umbilical cord blood samples (*, p < 0.05). Abbreviations: AUC, Area under the curve; PBS, phosphate-buffered saline.

signiﬁcant production of mature cells, with only minimal
expansion of primitive progenitor cell pool [34, 35]. Build-up
of differentiated cells in culture leads to the accumulation of
inhibitory soluble factors such as TGFb that limit the proliferation of primitive progenitor cells [31–33]. Similar to these
studies [33, 36], we found the frequency of progenitor cells
with high ALDH-activity declined as culture progressed, such
that the highest number of ALDHhi cells, CD341 cells, and
CD1331 cells was observed after 6 days of ex vivo expansion.
Extending culture to 9 days resulted in a drastic reduction in
the total number of primitive ALDHhi cells that remained.
Despite only low-frequency and transient recruitment to the
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pancreas after i.v.-transplantation, 6 day expanded ALDHhi
cells increased regenerating islet size, proliferation and capillary density, suggesting the induction of reparative proliferative and proangiogenic mechanisms, without evidence of new
islet formation via potential neogenic mechanism [28].
The endocrine pancreas is a highly vascularized tissue,
with 5–7 times more capillaries than the surrounding exocrine
tissue [37, 38]. A dense capillary network is required for b
cell to optimally sense blood glucose levels, and fenestrations
in the islet capillary endothelium is the most efﬁcient way for
insulin to be secreted by b cells into the systemic circulation
[39]. Thus, the islet capillary network is essential for optimal
C AlphaMed Press 2015
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Figure 4. Transplantation of expanded cells with high ALDH-activity increased islet size and b cell mass without increasing total islet
number. Representative photomicrographs of islets stained for insulin (brown) at day 42 in STZ-treated NOD/SCID mice transplanted
with (A) phosphate-buffered saline (PBS) (n 5 8), (B) bulk cells (n 5 9), (C) ALDHlo cells (n 5 9), or (D) ALDHhi cells (n 5 9). Compared
with PBS controls, or mice transplanted with Bulk or ALDHlo cells, mice transplanted with ALDHhi cells showed (E) increased islet size,
(F) equivalent islet number, and (G) increased total b cell mass. Data represent mean 6 SEM from 5 to 7 umbilical cord blood samples
(*, p < 0.05). Abbreviation: PBS, phosphate-buffered saline.

islet development function. In addition, hepatocyte growth
factor secreted by endothelial cells, and laminin expressed on
the basement membrane of the islet capillary network have
been shown to stimulate b cell proliferation [37, 40]. Collectively, these studies suggest that a endothelial / endrocine signaling axis, ﬁrst described by Lammert et al. in the
developing pancreas [41], plays an important role in supporting b cell function, and turnover throughout life [37]. Previously, we have shown that freshly isolated UCB ALDHhi cells
C AlphaMed Press 2015
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contain proangiogenic progenitor cells that improve perfusion
after transplantation into mice with hind-limb ischemia [22].
Here we establish that transplantation of culture-expanded
with high ALDHhi-activity enhanced revascularization in recovering islets, rather than extra-islet pancreatic tissue, suggesting the induction of an islet-speciﬁc proangiogenic program.
Similar to our previous studies [28, 29], islet cell proliferation
and improved islet function correlated with increased islet
capillary density, suggesting the activation of a hematopoietic
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Figure 5. Transplantation of expanded cells with high ALDH-activity increased cell proliferation within islets. Representative photomicrographs of proliferating (EdU1) cells (green) within insulin1 islets (red) at day 42 in STZ-treated NOD/SCID mice transplanted with (A)
phosphate-buffered saline (PBS) (n 5 6), (B) bulk cells (n 5 9), (C) ALDHlo cells (n 5 9), or (D) ALDHhi cells (n 5 9). Arrows represent
EdU1 / Insulin2 cells, arrowheads represent EdU1 / Insulin1 cells. Compared with PBS-injected controls, mice transplanted with
expanded ALDHhi cells showed (E) an increase in the frequency of islets with EdU1 cells, and (F) an increase total number of EdU1 cells
within islets. Data represent mean 6 SEM from 5 to 7 umbilical cord blood samples (*, p < 0.05). Abbreviation: PBS, phosphate-buffered
saline.

to endocrine cell signaling axis could be implicated in endocrine recovery.
Consistent with induction of islet-associated angiogenesis,
the ALDHhi cell subset demonstrated a proangiogenic transcriptional proﬁle compared with the more differentiated
ALDHlo subset. Proteins encoded by transcripts with increased
expression in expanded ALDHhi cells encoded for primitive
hematopoietic / endothelial progenitor markers (CD133,
CD34, TIE1, TIE2), and several proangiogenic cytokines
(ANGPT2, SEMA4A, MFGE8), and cell–matrix adhesion mole-
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cules (ITAG9, ICAM3, SELL). Thus, potential strategies to stimulate islet regeneration via proangiogenic drug or peptide
delivery may soon warrant direct investigation. For example,
mRNA encoding ANGPT2 and the Tie-2 receptor were both
upregulated in culture expanded ALDHhi cell subset. Although
ANGPT2 is considered a partial-agonist that competes for Tie2
receptor binding with ANGPT1, ANGPT2 is a complex regulator of vascular remodeling that plays a role in both vessel
sprouting and regression [42]. In the setting of angiogenic
sprouting ANGPT2 is rapidly induced with VEGF, whereas in
C AlphaMed Press 2015
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Figure 6. Transplantation of expanded cells with high ALDH-activity increased islet vascularization. Representative photomicrographs of
CD311 cells (green) within islets (red) at day 42 in STZ-treated NOD/SCID mice transplanted with (A) phosphate-buffered saline (PBS),
(B) bulk cells, (C) ALDHlo cells, or (D) ALDHhi cells. (E): Compared with mice injected with PBS (n 5 8), or transplanted with bulk cells
(n 5 9) or ALDHlo cells (n 5 9), mice transplanted with ALDHhi cells (n 5 9) showed increased vascularization within islets, but not in (F)
extra-islet areas. Data represent mean 6 SEM from 5 to 7 umbilical cord blood samples (*, p < 0.05). Abbreviation: PBS, phosphatebuffered saline.

the setting of vascular regression, ANGPT2 is induced in the
absence of VEGF [43, 44]. In addition, MFGE8 also known as
lactadherin, was upregulated by ALDHhi cells, and has been
shown to interact with avb3 integrins on endothelial cells, to
induce VEGFA-induced angiogenesis [45]. Because, pancreatic
b cells also express high levels of VEGF [37, 46, 47], it is plausible that MFGE8 and/orANGPT2 secreted by expanded
ALDHhi cells stimulate islet vascularization by supporting a
VEGF-dependent proangiogenic program [46]. Finally, the transcript for SEMA4A was also upregulated in culture expanded
C AlphaMed Press 2015
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ALDHhi cells. SEMA4A has been shown to act on PlexinD1
receptors to stimulate the release of VEGFA from macrophages [46]. Because macrophages are recruited to the pancreas after injury [47], SEM4A produced by UCB ALDHhi cells
may activate residual innate immune cells to stimulate VEGFA
release, a cascade that supports angiogenesis in the pancreas
of STZ-treated NOD/SCID mice. Despite the inherent complexity deciphering mechanisms of islet regeneration using xenotransplantation systems, our data suggest that proangiogenic
stimuli provided by ALDHhi cells, either during transit in the
STEM CELLS
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pancreas or via the circulation, may signiﬁcantly impact islet
regeneration via the generation of a proangiogenic niche.
These studies present several limitations to be considered
before clinical application. First, RosetteSep and AldeFluor
reagents are not cGMP compatible, and intended for research
purposes only. However, a cGMP-compliant product was previously used to perform clinical trials transplanting autologous
ALDHhi cells for critical limb ischemia [48], and ischemic heart
failure [49]. In addition, this product is currently being used
in the NIH-funded PACE trial for intermittent claudication [50].
cGMP grade reagents or alternatives will need to be used for
clinical applications. Second, this study emphasizes that only
the puriﬁed ALDHhi cell subset could stimulate endogenous
islet regeneration. Indeed, bulk cultured cells did not reverse
hyperglycemia despite the transfer of ﬁvefold greater cell
dose compared with repuriﬁed ALDHhi cells. We have previously observed a similar phenomenon when comparing fresh
ALDHhi cell transplantation to the injection of excess unpuriﬁed mononuclear cells [27]. Although additional studies are
required to decipher these data, differentiated hematopoietic
cells are known to secrete factors such as TGF-b that inhibit
progenitor cell proliferation [31]. Similarly, differentiated
ALDHlo cells that comprise > 80% of unpuriﬁed expanded cells
may similarly inhibit islet cell proliferation even in the presence of ALDHhi cells. Third, generation of adequate ALDHhi
cell numbers after expansion remains the primary limitation
to clinical application. A typical UCB sample contains approximately 400,000 ALDHhi cells. Thus, the threefold expansion
observed at day 6 yields approximately 1.2 million ALDHhi
cells. Since the recovery after each sort was > 90%, the
requirement to re-sort the cells was offset by expansion.
Although it is difﬁcult to estimate the number of cells that
would be required to treat human patients with diabetes, we
predict signiﬁcantly more cells will be required to treat
human diabetes. To address with this limitation, we are developing protocols aimed at efﬁciently expanding primitive
ALDHhi cells while limiting unwanted cell differentiation during
expansion, either by pathway inhibition/stimulation [31–33] or
by coculture strategies [51–53]. Boitano et al. [32] have found
that StemRegenin1 (SR1), an aryl hydrocarbon receptor antagonist, promotes the expansion of human hematopoietic stem
and progenitor cells with multilineage and long-term engraftment potential. When added to expansion culture this compound increased the number of primitive CD341 cells by 73fold when compared with cells cultured with growth factors
alone. Nonetheless, further optimization of ALDHhi cell expansion is required to increase the number of regenerative cells
available for clinical applications. Finally, human cell xenotransplantation requires the use of immunodeﬁcient mice to
permit human cell engraftment and function in the absence
of murine T- and B-lymphocytes. Even with STZ-treatment to
ablate b-cell function, overt autoimmunity is not present in
the NOD/SCID model. Thus, the capacity for ALDHhi cells to
stimulate expansion of human b-cell mass with or without
ongoing autoimmunity remains to be addressed using alternative in vitro and in vivo models.
We have previously used direct intra-pancreatic transplantation of fresh UCB ALDHhi cells to augment b cell proliferation in STZ-treated NOD/SCID mice [29]. Even with direct
delivery, only a low frequency UCB ALDHhi cells were detected
pancreas at day 42, but analyses at early time-points revealed
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transplanted ALDHhi cells created a regenerative niche surrounding islets within 4–7 days of transplantation as insulin
expression was recovered. In this study, human cells were not
detected in the pancreas at day 42 after i.v.-transplantation of
expanded cells, but expanded ALDHhi cells were recruited to
damaged islets at 7 days post-transplantation. Because intrapancreatic transplantation of ALDHhi cells improves the islet
regenerative response by increasing exposure to secreted
regenerative cues [29], limiting dilution analyses using intrapancreatic injection to determine the minimum number of
ALDHhi cells required to reverse hyperglycemia are warranted.
Furthermore, expanded ALDHhi cells do not survive long-term
in the pancreas, or may migrate away after regenerative programs are initiated. Thus, strategies to improve ALDHhi cell
delivery and retention in the human pancreas are also needed
for clinical applications.
Previous research from our group and others have shown
that high ALDH-activity is a conserved function of multiple
stem and progenitor cell lineages including endothelial precursors [26, 54], mesenchymal stem cells [26, 55, 56], neural progenitors [57, 58], muscle precursors [59], and pancreatic
endocrine precursors [60, 61] among others (reviewed in ref.
[62]). Therefore, the strategies employed in this manuscript
may have widespread application for selecting progenitor cells
with enhanced regenerative functions in multiple tissues. Fundamentally, ALDH is highly expressed in long-lived progenitor
cell types as a protective mechanism against oxidative stress.
In addition, ALDH is the rate-limiting enzyme in the production of retinoic acid, which demonstrates pleiotropic effects
on cell proliferation and differentiation via the retinoic acid
and retinoid-X receptor complexes. In the hematopoietic system, as progenitor cells differentiate, ALDH activity is generally reduced. Chute et al. have used chemical inhibitors of
ALDH1-activity to improve the expansion of CD341 hematopoietic SCID repopulating cells [33]. Thus, pharmacological
manipulation of retinoic acid production or signaling during
ex vivo expansion may provide a rational means to preserve
progenitor cell regenerative functions.

SUMMARY
In summary, these studies provide proof-of-concept that UCB
ALDHhi cells can be expanded under serum-free hematopoietic culture conditions, and it is only the culture expanded
primitive progenitor population (reselected ALDHhi cells) that
retains islet regenerative function after transplantation.
Although further elucidation of the mechanism by which
these progenitor cells stimulate islet regeneration is also
required to maximize islet regeneration in the face of autoimmunity, optimization of ex vivo expansion and reselection
strategies using high ALDH-activity, may ultimately lead to the
development of a cell based therapy to combat diabetes.
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